CD274 and familial pancreatic carcinoma: PD-L1 expression accounts for about 40% of patients both in esophageal/gastric and pancreatic cancers [48] and trials have been designed to evaluate the activity and toxicity of anti-CTLA-4 in combination with anti-PD-1/PD-L1 drugs in patients with GI non-colorectal tumors.